FORM OF WARRANT AGREEMENTWarrant Agreement • December 23rd, 2014 • Platinum Partners Value Arbitrage Fund, LP • Electromedical & electrotherapeutic apparatus • Delaware
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
Platinum Partners Value Arbitrage Fund L.P. c/o Platinum PartnersInvestment Agreement • December 23rd, 2014 • Platinum Partners Value Arbitrage Fund, LP • Electromedical & electrotherapeutic apparatus • Delaware
This Letter of Agreement, including the Exhibits attached hereto (collectively, this “Agreement”), sets forth the terms and conditions of the investment by Platinum Partners Value Arbitrage Fund L.P. and its affiliates (“Platinum”) and certain other investors (collectively with Platinum, the “Investors”) in Echo Therapeutics, Inc. (the “Company”). In consideration of the good and valuable consideration, including the mutual covenants, agreements and promises set forth in this Agreement and elsewhere, the receipt and sufficiency of which are hereby acknowledged, each of the Investors and the Company hereto agree as follows.
JOINT FILING AGREEMENTJoint Filing Agreement • March 6th, 2015 • Platinum Partners Value Arbitrage Fund, LP • Oil & gas field exploration services
The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of PEDEVCO Corp. dated as of March 6, 2015 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • March 7th, 2011 • Platinum Partners Value Arbitrage Fund, LP • Cable & other pay television services
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of a Statement on Schedule 13D/A-1 and all amendments thereto with respect to the Ordinary Shares, par value $0.0015 per share, of China Cablecom Holdings, Ltd. beneficially owned by each of them, and to the inclusion of this Joint Filing Agreement as an exhibit thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • November 30th, 2010 • Platinum Partners Value Arbitrage Fund, LP • Cable & other pay television services
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and all amendments thereto with respect to the Ordinary Shares, par value $0.0015 per share, of China Cablecom Holdings, Ltd. beneficially owned by each of them, and to the inclusion of this Joint Filing Agreement as an exhibit thereto.
JOINT FILING AGREEMENTJoint Filing Agreement • June 26th, 2015 • Platinum Partners Value Arbitrage Fund, LP • Services-prepackaged software
The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Infinity Augmented Reality, Inc. dated as of June 26, 2015 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • March 9th, 2016 • Platinum Partners Value Arbitrage Fund, LP • In vitro & in vivo diagnostic substances
The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Navidea Biopharmaceuticals, Inc. dated as of March 8, 2016 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
AGREEMENT JOINT FILING OF SCHEDULE 13DJoint Filing Agreement • April 18th, 2016 • Platinum Partners Value Arbitrage Fund, LP • Measuring & controlling devices, nec
The undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13D and any future amendments thereto reporting each of the undersigned’s ownership of securities of Implant Sciences Corporation, and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1 (k) under the Securities Exchange Act of 1934, as amended. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning the undersigned contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that the undersigned knows or has reason to believe that such information is inaccurate.
ContractSecurities Purchase Agreement • December 23rd, 2014 • Platinum Partners Value Arbitrage Fund, LP • Electromedical & electrotherapeutic apparatus • New York
JOINT FILING AGREEMENTJoint Filing Agreement • July 27th, 2012 • Platinum Partners Value Arbitrage Fund, LP • In vitro & in vivo diagnostic substances
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of a Statement on Schedule 13G and all amendments thereto with respect to the Common Stock, par value $0.001 per share, of Navidea Biopharmaceuticals, Inc. beneficially owned by each of them, and to the inclusion of this Joint Filing Agreement as an exhibit thereto.
